Zomato के कैसे रहे Q1 Results, Experts से जानिए कैसे बनाए निवेश की रणनीति । ETNow Swadesh

Summary

The video script discusses stock trading insights, emphasizing the importance of technical analysis and market momentum. It highlights a stock that has crossed the 230 mark and is showing promising technical developments, with a recommendation to consider a positional buy with a strict stop loss. The script also mentions positive revenue and profit growth, improved margins, and a significant year-over-year increase. It concludes with stock picks in the pharmaceutical sector, suggesting potential for good moves post-results.

Takeaways

• 📈 The stock has crossed the previous high of 230, indicating a strong momentum with increasing volumes.
• 🛑 For momentum traders, a strict stop-loss at the day's low is recommended.
• 📊 Technical indicators show a positive development, suggesting a potential target of 275-280 in two to three months.
• 🕒 Post-results volatility is expected, so positional buyers are advised to hold with a focus on the long-term potential.
• 💼 Revenue and profits have exceeded expectations, with a significant year-over-year EBITDA increase of over 100%.
• 🔄 Margins have doubled from 2.4% to 4.2%, aligning with market expectations.
• 💬 Management's commentary and press release will provide further insights on future prospects.
• 🍽️ Zomato's performance is highlighted as having strong technical support and potential for a sharp spike post-results.
• 💊 Sun Pharma's results were underwhelming, while other pharma stocks like Dr. Reddy's, Lupin, and Zydus showed strong performance.
• 🔍 Keeping an eye on market developments and technical charts is crucial for making informed trading decisions.

Q & A

What technical levels are being discussed in the script?

The technical level discussed is 230, and if the stock crosses above this level, it may have momentum to go higher.

What is recommended for those wanting to chase the momentum?

For those chasing momentum, it is recommended to use a strict stop loss at the day's low and consider buying BTST (Buy Today, Sell Tomorrow).

What should be considered after the results are announced?

After results are announced, it is advised to expect some fluctuation and consider a positional buy as the stock has a strong chart structure.

What is the expected price target in the next two to three months?

The expected price target in the next two to three months is 275-280.

How is the overall technical development described?

The overall technical development is described as very positive, with strong volumes and momentum building up.

What are the key financial performance highlights mentioned?

The key financial performance highlights include better-than-expected revenue and profit, with EBITDA more than doubling year-on-year.

What are the specific figures for EBITDA and margins?

EBITDA has reached 177 crores, and margins have improved from 2.4% to 4.2%.

What is the market's expectation regarding margins?

The market expected the margin figures, which have come in line with these expectations.

What should viewers keep an eye on regarding the company's updates?

Viewers should keep an eye on management commentary and the company's press releases for further updates and insights.

What other stocks in the pharma sector are performing well?

Other well-performing stocks in the pharma sector include Dr. Reddy's, Lupin, and Zydus.